Clinical coagulation assays are an integral part of diagnosing and managing patients with hemophilia; however, in this new era of bioengineered factor products and nonfactor therapeutics, problems have arisen with use of traditional coagulation tests for the quantification of several of these new products. Discussion over the use of one-stage clotting assays versus chromogenic substrate assays for clinical decision making and potency labeling has been ongoing for many years.
| I N T R O D U C T I O N
Clinical coagulation laboratory assays serve an important role in diagnosing and supporting treatment decisions for patients with bleeding disorders, yet current factor assays have gone largely unchanged for several decades. The prothrombin time (PT) and activated partial thromboplastin time (aPTT) serve as screening tests for an underlying factor deficiency, while specific factor activity assays by one-stage clotting assays (OSA) or chromogenic substrate assays (CSA) are used for diagnosis and monitoring factor levels following infusion of clotting factor concentrates for individuals with hemophilia A or B, factor VIII (FVIII) or factor IX (FIX) deficiency, respectively. Licensure of new, bioengineered factor concentrates to provide half-life extension [1] [2] [3] [4] [5] and an emerging group of nonfactor therapeutics, such as emicizumab-kxwh (Hemlibra, Roche), 6, 7 have heightened awareness of the limitations of our current clinical coagulation assays and fueled debate over the most clinically relevant assays. With these novel therapies, and several more products currently in various stages of clinical trial investigation, [8] [9] [10] problems have arisen for some products that cannot be measured accurately with traditional factor assays. Bioengineered factor products have modifications distinct from endogenous coagulation proteins for which the existing factor assays were designed.
OSA and CSA are used routinely in the U.S. and Europe for potency labeling of factor concentrate vials as well as clinical monitoring of patients.
While both types of assays indirectly measure FVIII activity (FVIII:C), they utilize different methodologies and are thus each subject to unique sources of variability and inaccuracy. The number of commercial reagents, and therefore the potential for interlaboratory variability, is more pronounced for OSA in comparison to CSA. In a 2006, UK National External Quality Assurance Scheme (NEQAS) survey of UK clinical laboratories, 25 different aPTT reagents, 20 different FVIII-deficient plasmas, and 13 different reference plasmas were in use for OSA, in contrast to only 5 different CSA kits. 11 Discrepancy between OSA and CSA is increasingly recognized with newer bioengineered factor products and certain F8 pathogenic variants. 12 This is not a new problem, however. Emergence of the first B domaindeleted (BDD) recombinant FVIII (rFVIII) clotting concentrate highlighted the clinical challenges that can arise when OSA and CSA are discordant.
Potency labeling assigned by CSA was 20% higher than when assayed using OSA. Since OSA underestimated factor activity it was recommended to either use CSA or OSA calibrated with the B-domain deleted product.
To overcome this challenge in the U.S. market, the amount of factor protein in each vial was increased 20%. 13, 14 Global hemostasis assays, such as the thrombin generation assay (TGA), thromboelastography (TEG) [and its modification, rotational thromboelastometry (ROTEM)], aPTT waveform analysis, and others are not currently in routine clinical by hematologists but in the age of novel hemostatic agents may offer alternative assessment of hemostasis in patients with bleeding disorders. 15 Currently, there are no CLIA-approved laboratory assays to quantify the hemostatic impact of emicizumab, and indeed the presence of even small quantities of emicizumab in patient plasma interferes with all aPTT based assays rendering them unreliable. Given the long half-life of emicizumab, 27.8 6 8.1 days, this interference can persist for up to 6 months after emicizumab discontinuation. 16 Providers caring for hemophilia patients in the age of bioengineered factor products and emicizumab must have a deeper understanding of the nuances of coagulation laboratory testing than ever before.
Here, we review methodology and limitations of commonly-used laboratory clotting tests for hemophilia, and how conventional and extended half-life factor concentrates, as well as nonfactor therapies, impact assay interpretation with particular attention to relevance when providing clinical care.
| Q U A N T I F Y I N G F A C T O R V I II AN D I X A C T IV I T Y
Routine diagnosis and management of patients with hemophilia depend on factor activity assays. 17, 18 Additionally, these assays support accurate potency labeling of clotting factor concentrates. 19 Assays must be able to accurately reflect baseline FVIII or FIX activity levels to establish the diagnosis and severity of individuals with hemophilia. Increasingly, postinfusion factor levels in conjunction with population pharmacokinetic (PK) models are being employed to generate individual PK profiles and personalize prophylaxis regimens. 20 25 The aPTT results are plotted on logarithmic-linear scale graph paper; all lines should run in parallel (parallelism). The FVIII activity of the sample is determined by identifying the dilution of the reference plasma that results in the same aPTT result as the sample plasma at the dilution designated 100 IU/dl for the reference plasma. In modern laboratory practice, the OSA is frequently automated. ple. 22 The second stage involves subsampling this mixture into normal plasma containing prothrombin and fibrinogen and measurement of the clotting time, which is correlated indirectly with the FVIII:C of the original sample. 18 From a laboratory perspective, the primary advantages of the two-stage clotting assay in comparison with the OSA are the lack of requirement for FVIII-deficient plasma and less interlaboratory variation.
The disadvantages include complexity, lack of automation, and lack of commercial reagents. 18 
| Chromogenic substrate assays
The CSA was originally developed in 1975 by Seghatchian and colleagues, Figure 2 . 31 In the first stage, which is similar methodologically to the two-stage clotting assay, dilutions of patient plasma are incubated with FIXa, factor X, phospholipids and calcium, resulting in formation of FXa proportional to the FVIII activity of the patient sample.
Small amounts of bovine thrombin are typically added in the first stage to facilitate activation of FVIII. 32 In the second stage, a FXa-selective chromogen is added. Hydrolysis of the substrate by FXa releases a chromophore (typically p-nitroaniline). The color intensity read by a photometer is proportional to the amount of FXa in the sample, and therefore also proportional to the FVIII activity. 30 The advantages and disadvantages of CSA from a laboratory perspective are like those of the two-stage clotting assay, with the exception that several commercial kits are available.
| Sources of variation/error in OSA and CSA
Each of these assays is susceptible to different sources of preanalytic and analytic errors. Those of key interest to clinicians are summarized in Table   1 . The OSA is susceptible to heparin contamination and lupus anticoagulants which can alter results; the CSA is not sensitive to either of these potential sources of error. 14, 33 Both assays are sensitive to the presence of direct oral anticoagulants, which result in a falsely low measurement of FVIII activity, 34 and both will report falsely low FVIII activity if the specimen is clotted because FVIII is consumed during clotting. OSA, but not CSA, is susceptible to "preactivation" of FVIII that can occur due to thrombin activation during venipuncture because of differences in the assay methodology. In contrast to OSA, CSA has an incubation period which allows for activation of all FVIII present making preactivation irrelevant. 35 Table 2 ). 48 The buffer used for dilution may influence results and numerous buffers are available commercially. 49 Finally, the instrument (analyzer) used to assess for clotting may be optical, measuring turbidity as clot forms, or mechanical, measuring increased viscosity as clot forms, which provides yet another potential source of interlaboratory variation. 50 Therefore, from a laboratory perspective, OSA may be less expensive and easier to automate than CSA, but it has numerous possible sources of inaccuracy. If several recommended OSA technical standardization procedures are followed, such as use of FVIII-deficient plasma with normal VWF levels and addition of albumin to all assay buffers, reduction in interlaboratory variation can be achieved. and CSA often demonstrate significant discrepancy, with some demonstrating potencies measured at up to 40% higher for the OSA 51, 52 and others demonstrating potencies measured at approximately 20% higher for the CSA. 33 When utilizing the OSA for labeling, the specific aPTT reagent used for OSA testing has been found to impact the measured potency results. 23 
| D I S C R E P A N T O S A A N D C S A RE S U LT S D U E TO F V I II PA T H O G E N I C V A R I A N T S
In the assessment of FVIII:C, clinically relevant discrepancy between assays is generally considered >20%. 
| Point mutations at the A1-A2-A3 interfaces
Appreciation of these pathogenic variants and their resultant impact requires a basic understanding of FVIII structure and function. FVIII is a heterodimer composed of a heavy chain (A1, A2, and B domains) and light chain (A3, C1, and C2 domains). 58 In the process of thrombincatalyzed conversion of FVIII to FVIIIa, the B domain is cleaved off and the result is a heterotrimer comprised of an A1 subunit, A2 subunit, and A3-C1-C2 subunit. The A2 subunit is only weakly associated with A1 and A3-C1-C2 subunits via an ionic interaction and is therefore susceptible to dissociation from the rest of the protein; this is how physiologic inactivation of FVIIIa occurs. 58 In patients with variants at the interfaces between where the A2 subunit interacts with the A1 and A3-C1-C2 subunits, such as those that disrupt potential intersubunit hydrogen bonds, Figure 3 , the measured FVIII:C by OSA is over twice that measured by CSA. This results from the longer incubation duration of CSA, which allows for more time for unstable FVIIIa to dissociate, resulting in lower measured FVIII activity. 
| N E W CLOT T I N G F A C T O R C ONC ENTR AT ES AND CLINICAL COAGULATION ASSAYS
Generally, OSA tends to accurately assess clinical recovery of plasma derived (pd) FVIII and full-length recombinant (r) factor concentrates but may underestimate the true FVIII:C of B-domain deleted (BDD) rFVIII products, with OSA measurements 20%-50% lower than CSA measurements. In lieu of using CSA for monitoring of these agents, potential solutions for optimizing OSA include product-specific OSA standards (as was done for ReFacto) or a conversion factor for OSA results (as was done for Afstyla). Afstyla, a single-chain rFVIII product, is an example of relatively predictable discrepancy between OSA and CSA which may be overcome by applying a conversion factor. If OSA is used, the label guidance is to multiply the FVIII activity by two. This approach, while feasible and relatively simple, introduces another potential source of error in clinical measurement. 61, 62 Several manufacturers have engineered modifications to the FVIII or FIX protein to slow clearance and thereby potentially reduce frequency of needed infusion for prophylaxis. 63 Successful prolongation of the half-life for rFVIII has been achieved via linkage with polyethylene glycol (PEG) and the human immunoglobulin G fragment crystallizable (Fc) region. 1,2 Similar technology, glycopegylation, Fcfusion, and albumin fusion, has been more successful with rFIX. [3] [4] [5] Use of the OSA to assay extended half-life FVIII and FIX products has product-specific and OSA reagent-specific challenges, Table 2 .
| EMIC IZUMAB AND COAGUL A TION TESTING
Emicizumab is a recombinant, humanized bispecific monoclonal antibody which serves the function of activated FVIII, bringing together FIXa and factor X (FX). Emicizumab is currently approved for bleeding prophylaxis in hemophilia A patients with inhibitors by the FDA, EMA, Japan and several other countries. 6, 7 It is administered subcutaneously once weekly with a longer dosing interval presently under investigation. Considerations for dosing in an acute bleed setting or perioperatively are also being explored as is safety and efficacy of emicizumab prophylaxis in hemophilia A patients without inhibitors. however, correlative human studies are not available. 66 
| Limitations of current clinical coagulation assays
Emicizumab interacts with all intrinsic pathway clotting-based laboratory assays, aPTT-based clotting assays measure the total clotting time of the intrinsic pathway of coagulation, including activation of FVIII to FVIIIa by thrombin; emicizumab does not require activation by thrombin and will therefore result in a supra-physiologically short clotting time. 16 Therefore, OSA performed in the presence of emicizumab would be expected to grossly overestimate FVIII:C. 7 While this is less clinically relevant in the inhibitor population for whom laboratory monitoring of FVIII:C is not generally clinically useful, standard inhibitor assays and monitoring of use of FVIII in low-titer inhibitor patients with breakthrough bleed events is not feasible with local laboratories.
| Quantifying hemostasis with emicizumab
The current FDA-approved CSA products commercially available in the U.S. are unable to assay the hemostatic impact of emicizumab as they use bovine coagulation proteins and thus are unable to detect emicizumab, a humanized antibody. 7 Therefore, while these assays cannot be used to estimate emicizumab activity, they could be used to quantify both exogenous and endogenous FVIII activity even in the presence of emicizumab, 16 has a much lower affinity for FIXa, binding it with a K D of 1.5 mM). 68 The duration of this effect will depend on the individual's FVIII clearance which is highly variable among patients and often not known a priori.
| N O V E L A P P RO A C H E S T O A S S A Y I N G H E MOS T A S IS
The global hemostasis assays including thrombin generation assays and viscoelastic assays may ultimately emerge as an option for the monitoring of hemophilia patients, particularly those treated with emicizumab or other nonfactor hemostatic agents currently in early phase clinical trials. [69] [70] [71] The reported clinical utility of these assays varies in part due to poor standardization of protocols and dependence on skill of individuals performing the assays as well as the intended application of the results. Novel strategies to capture hemostatic capacity in the broader context of the vessel microenvironment incorporating the complexity of interactions between endothelial cells, platelets, and coagulation factors are necessary. 72 Microfluidic technologies may also provide an opportunity for point of care testing and reduction of blood volume required. 73 
| CONCLUSIONS
The aPTT-based OSA is the primary assay used for routine monitoring and diagnosis of patients with hemophilia; however, use of CSA is gaining in popularity given the expanding armamentarium of factor concentrates available and the numerous product-specific considerations to keep in mind when using different analyzers and reagents for OSA.
First, some of the new bioengineered factor products and now the novel hemostatic agents such as emicizumab cannot be accurately measured by OSA and in some cases CSA. Knowing the specific situations in which OSA is unreliable and CSA should be used is critical for the safe use of factor concentrates in the modern era. Dialogue to share knowledge of aPTT reagents and patient factor products used locally benefits both hemophilia providers and the coagulation labora- 
